Variety of qualified clients: CDEC talked over the uncertainty in the volume of people with reasonably intense to severe hemophilia B in Canada suitable for etranacogene dezaparvovec. Scientific industry experts consulted by CADTH indicated that some people who will be labeled as acquiring delicate or reasonable condition might have a serious bleed